Yale University

EliScholar – A Digital Platform for Scholarly Publishing at Yale
Public Health Theses

School of Public Health

January 2013

Delivery Of Survivorship Care Plans: A Feasibility
Study
Kaleigh Joy Bulloch
Yale University, kaleigh.bulloch@yale.edu

Follow this and additional works at: http://elischolar.library.yale.edu/ysphtdl
Recommended Citation
Bulloch, Kaleigh Joy, "Delivery Of Survivorship Care Plans: A Feasibility Study" (2013). Public Health Theses. 1028.
http://elischolar.library.yale.edu/ysphtdl/1028

This Open Access Thesis is brought to you for free and open access by the School of Public Health at EliScholar – A Digital Platform for Scholarly
Publishing at Yale. It has been accepted for inclusion in Public Health Theses by an authorized administrator of EliScholar – A Digital Platform for
Scholarly Publishing at Yale. For more information, please contact elischolar@yale.edu.

Delivery of Survivorship Care Plans: A Feasibility Study
Kaleigh Bulloch
Melinda Irwin, PhD, MPH
Tara Sanft, MD
May 1, 2013

Abstract
Introduction: Despite the Institute of Medicines recommendation that all cancer survivors
be provided with a survivorship care plan (SCP) at the end of their treatment, very few
cancer centers have a mechanism for doing so. One of the major obstacles for providing
breast cancer patients SCPs is that breast cancer treatments are complex, occur over a
variable length of time, and are provided by many different providers, thus it is difficult
to determine when and who should provide SCPs to patients. However, the majority of
patients diagnosed with stage I-III will receive surgery and will continue to follow up
with their surgeon for several years following their active treatment phase. The purpose
of this study was first to determine if it is feasible to identify women for SCPs at their
postoperative visit and track them prospectively throughout their treatment. The
secondary aim of this study was to determine if participant’s knowledge about their
diagnosis, treatment, and risk for long term side effects improved after receiving their
SCP.
Methods: 75 English-speaking women over the age of 18 with stage I-III breast cancer
were enrolled at their postoperative appointment. The participants’ treatment progress
was tracked through the electronic medical record; the treatment information was
abstracted from the records and used to create treatment summaries. Once treatment was
completed, participants received the SCP during one of their scheduled follow-up
appointments. Knowledge of tumor, treatments, potential side effects, and screening
recommendations were assessed before receiving the SCP and again two months later.
Accuracy of responses at baseline and follow up were compared using the McNemar test.
Results: Accrual occurred during 42 clinic days between April 2011 and February 2012.
Of the patients who met the eligibility requirements 100% agreed to participate and we
were able to complete 100% of the SCPs regardless of where participants received their
treatments. Finally the surgical department was the only common department among all
our participants. We found that participants were more accurate in reporting details about
their tumor, treatments, screening recommendations, and potential side effects at follow
up than they were at baseline for most measures but the only statistically significant
changes were in identifying their stage (p = 0.0016), receiving 5-Fluorouracil during
chemotherapy (p= 0.0196), and having an increased risk of leukemia (p = 0.0348).
Conclusion: Women recently diagnosed with breast cancer are interested in receiving
survivorship care plans after treatment, as demonstrated by 100% accrual rate of eligible
patients approached in the postoperative visit. The postoperative visit in a surgical clinic
may provide the starting point for tracking a patient through treatment. Additionally
SCPs appear to improve patient knowledge in several important areas including basic and
specific treatment details, as well as screening recommendations and potential side
effects.
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Introduction
Breast cancer is the most frequently diagnosed cancer in American women with an
estimated 232,340 new cases of invasive breast cancer this year alone [1]. Though breast
cancer remains the second most common cause of cancer related death among women,
advances in screening and treatment have substantially improved breast cancer prognosis
[1]. Currently there are 2.9 million survivors of breast cancer, which account for more
than 40% of the female cancer survivors in the United States [1] .
Although breast cancer survivors are cured from their cancer, many patients face longterm side effects from their treatment. The risk of complications depends on the specific
treatment the patient received, but many common treatments can lead to lymphedema,
infertility, osteoporosis, cardiovascular disease, and secondary malignancies [2-5]. Both
patients and providers should be aware of these rare but serious complications and
monitor the patient’s health accordingly. Without universal health care records, the
burden of recalling details of their breast cancer treatment falls largely on the patients
after they are no longer being actively seen by their oncology team [6]. While patients are
seen frequently by medical professionals while undergoing cancer treatment, very little
information about the diagnosis, treatments, potential side effects, and future screening
recommendations is written down for patients [7]. The lack of written information is
problematic as it has been shown that many cancer patients feel overwhelmed and
anxious during their appointments which inhibits them from absorbing and understanding
the information [8]. Furthermore as soon as cancer patients are no longer undergoing
active treatment their frequent visits to their oncology team stop, which can cause anxiety
and feelings of abandonment [9]. Thus, not only can the lack of understanding of diseaserelated details have potential long-term consequences on the adequacy and
appropriateness of the survivor’s health, it can also have immediate psychological
consequences as patients feel unprepared to handle the transition from cancer patient to
cancer survivor [9]. These issues, coupled with the growing number of survivors, has led
to an increased awareness from providers and policy makers of the need for standardized
care strategies for cancer survivors that are no longer undergoing active treatment.
In 2006 The Institute of Medicine released a report outlining ten recommendations to
improve the care of cancer survivors [10]. One of the recommendations suggested
practitioners provide patients with survivorship care plans (SCPs), which is thought to
help patient’s transition from a “cancer patient” to a “cancer survivor” [10]. A
survivorship care plan is a document summarizing information about the cancer and
treatment. Essentially, it consists of four components, a treatment summary, information
about potential late or long-term side effects, surveillance and healthy lifestyle
recommendations, and identification of who will coordinate care. Though a growing
number of comprehensive cancer treatment facilities have survivorship clinics that
provide patients with survivorship care plans, they almost exclusively rely on physician
or patient self- referral to survivorship clinics [11, 12]. To our knowledge there are very
few comprehensive cancer treatment centers that report having a built-in component to
cancer care that insures all patients will receive survivorship care plans despite the
recommendation from the Institute of Medicine [11, 12]. Developing a strategy for
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providing SCPs to all cancer survivors is vital, as future accreditation of hospital cancer
programs by the Commission on Cancer of the American College of Surgeons will
require a system for doing so, beginning in 2015 [13].
There are several obstacles that have limited the wide dissemination of SCPs. One
previous barrier is that there was a lack of standardized templates. However, this
limitation was recognized by American Society of Clinical Oncology (ASCO) who
developed a cancer treatment template that allows providers a convenient way to store
information about a patient’s specific treatment and The University of Pennsylvania
Cancer Center who developed an online tool with the Livestrong Foundation that
provides standardized care plans, which provide information on long term side effects
and screening recommendations based on responses to treatment questions[14, 15]. One
limitation with the ASCO tool is the level of detail is such that it requires a physician to
complete the details of the patient’s history. The LIVESTRONG care plan is an on-line
care plan that patients can generate themselves; however, this requires the patient to
know which treatments they had. Studies have shown providers who have the
information can complete the relevant questions to develop these care plans in less than
ten minutes [16]. While the development of templates does solve a previous barrier it
does not eliminate the need for physician’s involvement in the creation of SCPs.
A second obstacle in providing SCPs to breast cancer patients is the diversity of treatment
pathways. Breast cancer treatments are complex, occur over a variable length of time
depending on the characteristics of the patient and the malignancy, and are provided by
many different medical specialists [12]. This diversity in treatment plans and providers
makes it difficult to systematically provide breast cancer survivors at the end of their
treatment through a particular specialist, as this requires coordination and communication
amongst the providers that is not always possible. However, the majority of patients
diagnosed with stage I-III will receive surgery and will continue to follow up with their
surgeon for several years following their active treatment phase [12]. If patients were
open to the idea of discussing survivorship at the time of surgery, the surgical oncologist
could serve as an ideal venue for identifying patients who will need to be given a SCP at
the end of their treatment.
The primary purpose of this study was to assess the feasibility of providing SCPs to
breast cancer survivors by enrolling them at the postoperative visit and tracking them
prospectively throughout their treatment. The secondary aim was to determine if
participant’s knowledge about their diagnosis, treatment, and risk for long term side
effects improved after receiving their SCP.
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Methods
The study was conducted at Smilow Cancer Hospital at Yale-New Haven, at the Smilow
Cancer Hospital Breast Center, a nationally accredited comprehensive breast cancer
program. The Human Investigation Committee at Yale University approved all of the
study procedures and documents and all participants gave written informed consent.
Participants and Recruitment
Participants were enrolled between April 2011 and February 2012 during their
postoperative appointment. Female patients were eligible for the our study if they had
pathologically confirmed stage I, II, or III breast cancer, had their breast cancer surgery at
Smilow Cancer Hospital, and were over 18 years of age. Participants were excluded from
participation if they were not fluent in English, or if they had a concurrent cancer
diagnosis.
Study Design
Once the participant was enrolled, we began tracking their cancer treatment through the
electronic medical record. At the end of a participant’s active treatment we reviewed the
relevant medical records and abstracted the necessary clinical information needed to
create treatment summaries using the ASCO template, and the Livestrong Care Plan
generator. Participants were contacted by a research administrator as they approached the
end of their active treatment and were scheduled for a baseline (post-treatment) interview
that took place 15 minutes before or after an existing appointment in the cancer center.
We defined the end of treatment as the time at which patients had completed their
radiation and/or chemotherapy treatments and had been initiated on hormonal therapy, if
applicable. If the patient did not receive any adjuvant therapy the end of treatment was
defined as the appointment in which they were informed their active treatment was
completed. The only exception to this protocol was patients being treated with a
yearlong course of Herceptin who could still be completing their chemotherapy at the
time of the baseline appointment.
During the baseline appointment participants were asked to complete three selfadministered surveys about their demographic information, medical history, and
knowledge of the breast cancer surveillance recommendations without assistance (see
measures). The participants were then given a written copy of their personalized care plan
with a Yale cover letter explaining the purpose of the document. Two months after the
baseline appointment participants were mailed the follow up questionnaires and a prepaid
return envelope. Participants who did not return the follow-up surveys within a month of
the mailing were contacted by telephone and were re-mailed the surveys.
Measures
Information on demographics, cancer diagnosis, cancer treatments, and knowledge of
follow up recommendations was collected via the self-administered questionnaires at the
baseline visit. The first questionnaire asked basic demographic information and included
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questions pertaining to the participant’s age, racial/ethnic group, education, marital status,
employment, reproductive history, and serious comorbidities. The second questionnaire
was used to assess the participant’s knowledge of their treatment prior to receiving the
SCP including questions on the clinical pathology of their tumor at diagnosis, the types of
treatment they received including questions on specific medications prescribed and dates
that they were administered each treatment. The final questionnaire asked the participant
specific questions about long-term side effects of breast cancer treatment, and screening
recommendations for breast cancer survivors. In addition it asked participants to rate their
assessment of their own knowledge about their stage, treatments, surveillance guidelines,
and potential long-term side effects on a scale from 0 to 10 where 0 was defined as no
knowledge and 10 was defined as expert level knowledge. The second and third
questionnaires were also used at follow up but the third questionnaire had one additional
question asking if the participant was satisfied with her SCP.
Statistical Analysis
We originally intended to characterize reasons why women choose not to enroll in our
study, however as we enrolled all of the women who met our eligible criteria this was not
necessary. In addition we had intended to compare the characteristics of participants who
received their SCP to the characteristics participants who did not receive their SCP using
chi-square analysis, t-tests, and logistic regression to determine which characteristics of
the participant were associated with the receipt of an SCP, however we again found that
we were able to give all of our enrolled participants an SCP.
Analysis of the participant’s knowledge before and after the SCP was limited to
participants who returned both the baseline and follow up surveys. The comparisons
between participants who did not return the follow up surveys to those who did return the
follow up surveys was done using chi-square tests for categorical variables and t tests for
continuous variables. Responses to knowledge questions were dichotomized as correct if
the answer was correct or incorrect if the participants choose “don’t know” or marked the
incorrect answer. We used the McNemar test to conduct the comparison of correct
answers chosen at baseline to those chosen at follow.
All of our analyses were conducted using SAS 9.3 (SAS Institute, Cary, NC) at a
significance level of <0.05.
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Results
We screened 129 post-operative visit diagnoses to identify eligible participants patients
for enrollment between April 2011 and February 2012, 54 people were not eligible to
participate due to non-invasive carcinomas (n= 46), metastatic disease (n = 3), and nonEnglish speaking (n = 5) (Figure 1). Of the 75 post-operative visit diagnoses that met the
inclusion criteria, 75 patients were approached and all 75 agreed to participant, for a
100% enrollment rate. We were able to track the treatment progress and complete the
SCPs for all 75 participants. Further examination of the participants’ clinical pathology
during the creation of the SCPs revealed that three of the participants did not have
invasive breast cancer and one was unable to read in English. Though we provided these
women with their SCPs, as these patients did not meet the eligibility requirements they
were excluded from further evaluation. During the baseline assessment three participants
withdrew from the study and one was released from the study due to the development of
metastatic disease during the interim between enrolment and completion of initial therapy
thus our final sample size was 67 women. Of the 67 eligible participants who completed
the baseline questionnaire, 51 also completed the follow up assessment for a follow up
rate of 76.1%.
Demographic and clinical characteristics for the 51 women included in the present
analysis are shown in Table 1. We observed that a significantly larger proportion of nonHispanic whites (p= 0.0014) and women with private insurance completed the follow up
surveys (p = 0.0184). The average age at diagnosis was 56.8 years; and the predominant
racial/ethnic group was non-Hispanic white (92.2%). The majority of our participants
were highly educated and married. None of our participants were uninsured. 47.1% of our
participants were diagnosed with stage I breast cancer, 37.3% with stage II, and 15.7%
with stage III. 74.5% of our sample was ER positive, 68.6% were PR positive, 11.8%
were HER2 positive, and 19.6% were triple negative. The majority of our sample
received hormonal therapy (76.5%) and radiation (70.6%), whereas just over half
(56.9%) underwent adjuvant chemotherapy. Finally 25.5% of our participants also
attended the Survivorship Clinic at Yale Cancer Center.
The accuracy of responses for tumor characteristics and treatments received at baseline
and follow up are shown in Table 2. A greater number of participants selected correct
responses at follow up for the majority of the questions, however the only statistically
significant improvements in accuracy between baseline and follow up was the
participants knowledge of their stage at diagnosis (p= 0.0016) and correct identification
of being prescribed 5-Fluorouracil (p=0.0196). The accuracy of responses for long-term
side effects and screening recommendations at baseline and follow up are shown in Table
3. Again more participants choose the correct response for the long-term side effects, and
screening recommendations at follow up than at baseline. However, the only statistically
significant change was that more women in our sample knew that some breast cancer
treatments increased the risk of developing Leukemia (p= 0.0348).
Table 4 shows the participants perception of their own knowledge at baseline and at
follow up. At both baseline and follow up the majority of participants reported having
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high knowledge of their stage (60.4%, and 66.7% respectively), treatments they received
(69.4%, and 71.4% respectively), and surveillance guidelines (61.4%, and 54.6%
respectively). However at both baseline and follow up less than half of the participants
reported having high knowledge of potential side effects of their treatment (50.0%, and
42.9% respectively). There was no statistical difference in responses before and after
receiving the SCP.
The accuracy of responses of participants who attended the Survivorship Clinic at Yale
Cancer Center was compared to the accuracy of responses of participants who did not. At
follow up participants who attended the Survivorship Clinic were not more accurate in
identifying details of their disease or treatment. However, participants who attended the
Survivorship Clinic at Yale were more accurate in the identification of the treatment side
effects including lymphedema (p= 0.0462), cardiac problems (p= 0.0225), leukemia
(p=0.0428), neuropathy (p = 0.0302), and menopausal symptoms (p = 0.0193). Despite
this, the participants who attended the Survivorship Clinic did not have statistically
higher perceived knowledge at follow up.
Finally the majority of participants (83.6%) reported being satisfied with their SCP.
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Discussion
Despite the Institute of Medicine’s recommendation that cancer centers provide SCPs to
all cancer survivors, few cancer centers have systems for doing so. The primary goal of
this study was to determine if it is feasible to identify women during their postoperative
visit and track them prospectively through their treatment with the goal of giving a
survivorship care plan after completion of initial treatment. Previous research suggests
that women prefer to discuss survivorship at the end of their treatment, as they are
already overwhelmed with information about their diagnosis and treatment options during
their active treatment phase [17]. However, introducing survivorship during the
postoperative visit could be advantageous, as it eliminates one of the chief logistical
obstacles in broadly providing care plans, which is that not all breast cancer patients
undergo the same treatment progression and thus it is difficult to identify a suitable time
after which the provider should distribute SCPs. Though adjuvant treatment pathways
differ between patients, nearly all breast cancer patients receive surgery and thus surgery
clinics could provide an opportunity to identify the majority of patients who will
eventually be cancer survivors. Moreover, like many cancer centers, at Yale breast cancer
patients are recommended to follow up with their surgical providers every 6 months for
the first 3 years, and every year thereafter until 5 years post operative suggesting that
surgical clinics may be the ideal place to provide patients with completed SCPs after their
active treatment [18].
In this study we demonstrated women are open and interested in survivorship care plans
even moments after they have learned the details of their diagnosis and potential
treatments, as demonstrated by 100% accrual rate of eligible patients approached in the
postoperative visit. Our sample population had a wide range of treatments, 70.6%
received radiation, 56.9% received chemotherapy, and only 47.1% received both.
Therefore, the surgical office is the only common setting to which every woman with
early stage breast cancer is guaranteed to be seen. Consequently, the postoperative visit in
a surgical clinic appears to be a viable option to start tracking a patient through treatment,
which in turn may provide a feasible model for delivering survivorship care plans to all
breast cancer survivors. Though this study has demonstrated the patient’s willingness to
discuss survivorship in their post-operative appoints further research is needed to
determine the cost effectiveness of a SCP system in the surgical clinic compared to other
models like stand-alone survivorship clinics.
The secondary goal of this study was to determine if SCPs had an effect on the patients
knowledge about their diagnosis, treatments, and risk of long-term complications. We
found that participant’s knowledge improved after they received their SCPs, however
only a few of these changes were statistically significant. There have been two other
recent studies that have explored the effectiveness of SCPs on breast cancer survivor’s
knowledge, one of which found them to be effective and one of which found them to be
ineffective [19, 20]. While both studies had methodological constraints the Grunfeld et al
finding that SCPs were not effective has been heavily criticized as both the intervention
and control groups were given similar information, thus it did not truly compare the
effectiveness of SCPs[21, 22]. Our findings add the evidence and suggest that SCPs are
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an effective method of improving cancer survivor’s knowledge. Given the inconsistency
in findings as well as the scarcity of studies further investigation is needed to determine
the effectiveness of SCPs. However, if SCPs are found to have even a moderate effect on
knowledge this could have significant implications in survivor’s health at a minimal cost.
At both baseline and follow up women felt that they were well informed on most cancer
related topics with over half reporting high levels of knowledge on their stage, treatments
received, and surveillance guidelines even though they were not accurate in reporting the
details of their treatments. This inconsistency in perceived knowledge and actual
knowledge has potential consequences as it might prevent women from informing their
future providers accurate information, or verifying information with their oncology
providers. Additionally there was no statistical difference in perceived knowledge for
stage, treatments received, surveillance guidelines, or potential side effects, but less
women reported having high knowledge on surveillance guidelines and potential side
effects at follow up than at baseline. Though we provided women with their SCP and
orientated them to relative information we did not specifically point out the information
page-by-page. We relied on the participants to read the document and ask their provider
if they had questions or needed clarification. Perhaps a better solution is giving a SCP
plus dedicating time to reviewing this, essentially providing a “transition visit” where the
information is reviewed.
There are a few notable limitations to this study. The first is that Smilow Cancer
Hospital has a survivorship clinic, which is available to all patients who are interested in
receiving survivorship care at the end of their treatment. 25.5% of our participants also
participated in the clinic between baseline and follow up. Attending the survivorship
Clinic may have influenced these participants knowledge who had higher levels of
knowledge on some metrics at follow up, however these women also had a high
knowledge at baseline suggesting that healthier, more educated women seek out the
survivorship clinic. A second limitation is that we collected information in a single health
care system that serves a largely Caucasian, highly educated, and insured population. It
may be difficult to generalize these findings to a different population. Finally as this was
a feasibility study we did not have a control group, future studies should randomize
patients to receive a SCP or to usual care to determine if the SCP is more useful than the
current system.
To our knowledge this is the first study to demonstrate the effectiveness of approaching
women for SCPs in their postoperative appointment, and one of the few studies that have
examined the effectiveness of SCPs on patient knowledge. The strengths of this study are
that we were able to show that patients are receptive to survivorship care as soon as their
postoperative appointments. Identifying patients for survivorship following their
operation could significantly increase the number of patients who receive SCPs in
comprehensive cancer centers.
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Figure 1: Flow of participant enrollment
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Table 1: Baseline demographics and clinical characteristics of study participants included in the
analysis compared with those not included
Age, years
Mean ± SD
Race/Ethnicity
Non-Hispanic white
Non-Hispanic black
Hispanic/Latino
Other
Education
Less than high school diploma
High school diploma
Some college
Baccalaureate Degree
Professional or Graduate Degree
Marital status
Single
Married/cohabiting
Widow
Separated/divorced
Insurance
Private Insurance
Public Insurance
Uninsured
Disease stage
Stage I
Stage II
Stage III
Type of Treatment
Radiation
Chemotherapy
Hormonal therapy
Hormone Receptor Status
Estrogen Receptor
Progesterone Receptor
HER2
Triple Negative
Attended Yale Survivorship Clinic
Yes
No

Complete Data n=51

55.9 ± 12.6

56.8 ± 12.5

56 (83.6%)
3 (4.5%)
2 (3.0%)
6 (9.0%)

47 (92.2%)
0 (0.0%)
1 (2.0%)
3 (5.9%)

0.0014

4 (6.0%)
9 (13.4%)
14 (20.9%)
17 (25.4%)
23 (34.3%)

1 (2.0%)
6 (11.8%)
11 (21.6%)
14 (27.5%)
20 (37.3%)

0.1509

6 (9.0%)
41 (61.2%)
8 (11.9%)
12 (17.9%)

4 (7.8%)
34 (66.7%)
6 (11.8%)
7 (13.7%)

0.2419

40 (60.6%)
26 (39.4%)
0 (0.0%)

34 (68.0%)
16 (32.0%)
0 (0.0%)

0.0184

32 (47.1%)
25 (36.8%)
11 (16.2%)

24 (47.1%)
19 (37.3%)
8 (15.7%)

0.8619

43 (65.2%)
36 (53.7%)
52 (77.6%)

36 (70.6%)
29 (56.9%)
39 (76.5%)

0.1215
0.3956
1.0000

51 (76.1%)
47 (70.2%)
8 (11.9%)
12 (17.9%)

38 (74.5%)
35 (68.6%)
6 (11.8%)
10 (19.6%)

0.7429
0.7597
1.0000
0.7159

16 (23.9%)
51 (76.1%)

13 (25.5%)
38 (74.5%)

0.7429

*Numbers may not sum due to missing data, and percentages may not sum to 100% due to rounding.
† P-value for t-test for continuous variables χ2 test for categorical variables.
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0.2747

Table 2: Accuracy of knowledge of basic and specific treatment details at baseline and follow up
Basic Treatment Information
Baseline
Follow Up
P value†
Stage
Accurate
37 (72.6%)
47 (92.2%)
0.0016
Inaccurate
14 (27.5%)
4 (7.8%)
Radiation (y/n)
Accurate
51 (100%)
51 (100%)
n/a
Inaccurate
0 (0.0%)
0 (0.0%)
Chemotherapy (y/n)
Accurate
51 (98.1%)
51 (98.1%)
n/a
Inaccurate
1 (1.9%)
1 (1.9%)
Hormone Therapy (y/n)
Accurate
35 (68.6%)
41 (80.4%)
0.0833
Inaccurate
16 (31.4%)
10 (19.6%)
Specific Treatment Information
5- Fluorouracil
Accurate
19 (65.5%)
26 (89.7%)
0.0196
Inaccurate
10 (34.5%)
3 (10.3%)
Cyclophosphamide
Accurate
21 (72.4%)
23 (79.3%)
0.4142
Inaccurate
8 (27.6%)
6 (20.7%)
Methotrexate
Accurate
21 (72.4%)
25 (86.2%)
0.1573
Inaccurate
8 (27.6%)
4 (13.8%)
Anthracyclines
Accurate
20 (69.0%)
22 (75.9%)
0.4142
Inaccurate
9 (31.0%)
7 (24.1%)
Carboplatin
Accurate
21 (72.4%)
25 (86.2%)
0.1025
Inaccurate
8 (27.6%)
4 (13.8%)
Taxanes
Accurate
25 (86.2%)
24 (82.8%)
0.6547
Inaccurate
4 (13.8%)
5 (17.2%)
Tamoxifen
Accurate
46 (90.2%)
47 (92.2%)
0.5637
Inaccurate
5 (9.8%)
4 (7.8%)
Anastrozole
Accurate
46 (90.2%)
49 (96.1%)
0.1797
Inaccurate
5 (9.8%)
2 (3.9%)
Letrozole
Accurate
46 (90.2%)
47 (92.2%)
0.6547
Inaccurate
5 (9.8%)
4 (7.8%)
Aromasin
Accurate
48 (94.1%)
49 (96.1%)
0.5637
Inaccurate
3 (5.9%)
2 (3.9%)
*Numbers may not sum to 51 as some participants did not receive each therapy, and percentages may not sum to 100% due to rounding.
† P value for McNemar test.
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Table 3: Accuracy of knowledge of screening recommendations and side effects at baseline and follow up
Baseline
Follow up
How often should you see your oncologist
Correct
33 (64.7%)
37 (72.6%)
Wrong
18 (35.3%)
14 (27.5%)
Frequency of Mammograms
Correct
24 (47.1%)
28 (54.9%)
Wrong
27 (52.9%)
23 (45.1%)
Potential Side Effects
Lymphedema
Yes
35 (71.4%)
40 (83.3%)
No
7 (14.3%)
4 (8.3%)
Do Not Know
7 (14.3%)
4 (8.3%)
Bone Loss
Yes
33 (67.4%)
34 (69.4%)
No
7 (14.3)
8 (16.3%)
Do Not Know
9 (18.4%)
7 (14.3%)
Infertility
Yes
22 (45.8%)
24 (50.0%)
No
15 (31.3%)
13 (27.1%)
Do Not Know
11 (22.9%)
11 (22.9%)
Cardiac Problems
Yes
21 (43.8%)
24 (50.0%)
No
14 (29.2%)
13 (27.1%)
Do Not Know
13 (27.1%)
11 (22.9%)
Fatigue
Yes
40 (80.0%)
42 (87.5%)
No
6 (12.0%)
4 (8.3%)
Do Not Know
4 (8.0%)
2 (4.2%)
Leukemia or blood cancer
Yes
18 (36.0%)
23 (46.9%)
No
16 (32.0%)
16 (32.7%)
Do Not Know
16 (32.0%)
10 (20.4%)
Neuropathy
Yes
20 (40.0%)
26 (54.2%)
No
14 (28.0%)
10 (20.8%)
Do Not Know
16 (32.0%)
12 (25.0%)
Limb Swelling
Yes
28 (56.0%)
34 (70.8%)
No
11 (22.0%)
4 (8.2%)
Do Not Know
11 (22.0%)
10 (20.8%)
Nerve Damage
Yes
21 (42.0%)
25 (55.6%)
No
15 (30.0%)
8 (17.8%)
Do Not Know
15 (28.0%)
12 (26.7%)
Menopausal Symptoms
Yes
33 (67.4%)
33 (67.4%)
No
8 (16.3%)
9 (18.4%)
Do Not Know
8 (16.3%)
7 (14.3%)
*Numbers may not sum to 51 due to missing data, and percentages may not sum to 100% due to rounding. † P value for McNemar test.
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P value†
0.3458

0.3938

0.0956

0.7815

0.5271

0.3657

0.5271

0.0348

0.1088

0.1336

0.2850

1.0000

Table 4: Perceived knowledge at baseline and follow up
Baseline
Stage
High
29 (60.4%)
Medium
15 (31.3%)
Low
4 (8.3%)
Treatments Received
High
35 (71.4%)
Medium
10 (20.4%)
Low
4 (8.2%)
Surveillance Guidelines
High
27 (55.1%)
Medium
14 (28.6%)
Low
8 (16.3%)
Potential Side Effects
High
24 (48.9%)
Medium
16 (32.7%)
Low
9 (18.4%)
† P value for McNemar test.
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Follow up

P value†

32 (66.7%)
11 (22.9%)
5 (10.4%)

0.6594

35 (71.4%)
12 (24.5%)
2 (4.1%)

0.7212

26 (53.1%)
20 (40.8%)
3 (6.1%)

0.2474

21 (42.9%)
23 (46.9%)
5 (10.2%)

0.2504

